BECN1 and in situ carcinoma: In line, here, we showed that siRNAs against: ATG5, ATG7, or Beclin1 introduced to normoxic or hypoxic lung cancer cells prior to CIS treatment, did not changed their ability to induce senescence or senescence escaping.